The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Gene Therapy with Brain-Derived Neurotrophic Factor As a Protection: Retinal Ganglion Cells in a Rat Glaucoma Model
Abstract
PURPOSE: To develop a modified adenoassociated viral (AAV) vector capable of efficient transfection of retinal ganglion cells (RGCs) and to test the hypothesis that use of this vector to express brain-derived neurotrophic factor (BDNF) could be protective in experimental glaucoma. METHODS: Ninety-three rats received one unilateral, intravitreal injection of either normal saline (n = 30), AAV-BDNF-woodchuck hepatitis posttranscriptional regulatory element (WPRE; n = 30), or AAV-green fluorescent protein (GFP)-WPRE (n = 33). Two weeks later, experimental glaucoma was induced in the injected eye by laser application to the trabecular meshwork. Survival of RGCs was estimated by counting axons in optic nerve cross sections after 4 weeks of glaucoma. Transgene expression was assessed by immunohistochemistry, Western blot analysis, and direct visualization of GFP. RESULTS: The density of GFP-positive cells in retinal wholemounts was 1,828 +/- 299 cells/mm(2) (72,273 +/- 11,814 cells/retina). Exposure to elevated intraocular pressure was similar in all groups. Four weeks after initial laser treatment, axon loss was 52.3% +/- 27.1% in the saline-treated group (n = 25) and 52.3% +/- 24.2% in the AAV-GFP-WPRE group (n = 30), but only 32.3% +/- 23.0% in the AAV-BDNF-WPRE group (n = 27). Survival in AAV-BDNF-WPRE animals increased markedly and the difference was significant compared with those receiving either AAV-GFP-WPRE (P = 0.002, t-test) or saline (P = 0.006, t-test). CONCLUSIONS: Overexpression of the BDNF gene protects RGC as estimated by axon counts in a rat glaucoma model, further supporting the potential feasibility of neurotrophic therapy as a complement to the lowering of IOP in the treatment of glaucoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AAV vector delivery via intravitreal (IVT) injection is a minimally invasive procedure that offers the potential for broad inner retinal transduction, providing significant transgene expression in the ganglion cell layer (GCL) (10, 14–17), and in particular in retinal ganglion cells (RGCs) (17–20).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [20]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,705
Heijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320
Number of people with glaucoma worldwide.
Quigley, H. A. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.5.389 · Cited by 2,998
Self-citation(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00223-2 · Cited by 1,599
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Astrocyte glutamate transport: Review of properties, regulation, and physiological functions
Anderson, C. M., & Swanson, R. A. (2000) · Glia · doi:10.1002/1098-1136(200010)32:1<71::aid-glia70>3.0.co;2-0 · Cited by 1,242
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationSommer, A. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080080050026 · Cited by 1,178
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.
Quigley, H. A., Nickells, R. W., Kerrigan, L. A., Pease, M. E., Thibault, D., & Zack, D. J. (1995) · PubMed · Cited by 935
Self-citation
Cited by
Quigley, H. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61423-7 · Cited by 1,121
Self-citationThe molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Bi, A., Cui, J., Ma, Y.-P., Olshevskaya, E., Pu, M., Dizhoor, A. M., & Pan, Z.-H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.026 · Cited by 771
Weinreb, R. N., Leung, C. K. S., Crowston, J. G., Medeiros, F. A., Friedman, D. S., Wiggs, J. L., & Martin, K. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.67 · Cited by 632
Self-citationCuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
Johnson, T. V., Bull, N. D., Hunt, D. P., Marina, N., Tomarev, S. I., & Martin, K. R. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4509 · Cited by 344
Self-citationLeaver, S. G., Cui, Q., Plant, G. W., Arulpragasam, A., Hisheh, S., Verhaagen, J., & Harvey, A. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302791 · Cited by 271
Understanding mechanisms of pressure-induced optic nerve damage
Morrison, J. C., Johnson, E. C., Cepurna, W., & Jia, L. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.08.003 · Cited by 261
Effect of CNTF on retinal ganglion cell survival in experimental glaucoma
Pease, M. E., Zack, D. J., Berlinicke, C., Bloom, K., Cone, F., Wang, Y., Klein, R. L., Hauswirth, W. W., & Quigley, H. A. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3013 · Cited by 222
Self-citationEfficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208
Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1041-8 · Cited by 175
Self-citationTejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
“Several studies have shown that BDNF transiently delays RGC death in glaucoma [172,173].”
BackgroundNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Gene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
Neuroprotection for glaucoma: Requirements for clinical translation
Levin, L. A., Crowe, M. E., Quigley, H. A., Cordeiro, M. F., Donoso, L. A., Liao, Y. J., Libby, R. T., Masland, R. H., Nickells, R. W., Sieving, P. A., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2016.12.005 · Cited by 66
Self-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Liu, Y., Eastwood, J. D., Alba, D. E., Velmurugan, S., Sun, N., Porciatti, V., Lee, R. K., Hauswirth, W. W., Guy, J., & Yu, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00333-6 · Cited by 19
Self-citationMutation-independent therapies for retinal diseases: focus on gene-based approaches
Carrella, S., Indrieri, A., Franco, B., & Banfi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.588234 · Cited by 14
“AAV-mediated delivery of Fibroblast growth factor-2, or delivery of the BDNF gene leads to significant increase in RGC survival and reduced RGC axons loss after optic nerve injury or induction of intraocular pressure (IOP) (Martin et al., 2003; Sapieha et al., 2006).”
BackgroundInfluentialMitochondrial Transfer of the Mutant Human ND6T14484C Gene Causes Visual Loss and Optic Neuropathy
Yu, H., Sant, D. W., Wang, G., & Guy, J. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.1 · Cited by 13
Costa-Verdera, H., Jamwal, D., Fabyanic, E., Hippen, A., Salvatore, M., Du, A., Majowicz, A., Markusic, D., Chatterton, J. E., Haurigot, V., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1799327 · Cited by 2
“…delivery via intravitreal (IVT) injection is a minimally invasive procedure that offers the potential for broad inner retinal transduction, providing signi fi cant transgene expression in the ganglion cell layer (GCL) (10, 14 – 17), and in particular in retinal ganglion cells (RGCs) (17 – 20).”
Influential
Metadata
- Authors
- Martin, K. R. G., Quigley, H. A., Zack, D. J., Levkovitch-Verbin, H., Kielczewski, J., Valenta, D., Baumrind, L., Pease, M. E., Klein, R. L., & Hauswirth, W. W.
- Affiliations
- Johns Hopkins University (US)
- Departments of Pharmacology and Therapeutics and
- University of Florida (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2003-10-01
- Volume
- 44
- Issue
- 10
- Pages
- 4357
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2157252223
- Cited by
- 362
- References
- 68
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 10 · 2022: 15 · 2021: 14 · 2020: 18 · 2019: 12 · 2018: 14 · 2017: 14 · 2016: 24 · 2015: 27 · 2014: 16 · 2013: 15 · 2012: 8
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Eye Institute (#EY01765, EY 02120, P30EY001765)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- gene therapy, brain-derived neurotrophic factor, retinal ganglion cells, glaucoma, adeno-associated virus vectors, neuroprotection, axonal loss, intraocular pressure elevation, laser-induced glaucoma, neurotrophic therapy
- MeSH terms
- Dependovirus, Animals, Axons, Cell Count, Cell Survival, Disease Models, Animal, Genetic Vectors, Glaucoma, Intraocular Pressure, Luminescent Proteins, Optic Nerve Diseases, Retinal Ganglion Cells, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Transfer Techniques, Brain-Derived Neurotrophic Factor, Cytoprotection, Green Fluorescent Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.